---
title: "Research"
format:
  html:
    toc: true
    number-sections: false
    smooth-scroll: true
---

## ðŸ“ˆ Pharmacometrics in metablolic and neuroscience therapeutic areas

**Advisor-Pharmacometrician, Eli Lilly and Company (Jun 2024 - Present)**\
Global PK/PD/PMx department\
*Supervisor: Dr. Nieves Velez de Mendizabal*

My current research at Eli Lilly and Company focuses on the development and application of quantitative pharmacology and pharmacometrics to support drug development in metabolic and neuroscience therapeutic areas.

## ðŸ§  Alzheimer's Disease & Type 2 Diabetes & Blood-Brain Barrier Dysfunction

**Graduate Research Assistant, University of Minnesota (Nov 2019 â€“ May 2024)**\
Department of Pharmaceutics\
*Advisor: Dr. Karunya K. Kandimalla*

My dissertation research focused on understanding how amyloid-beta (AÎ²) peptides and insulin resistance contribute to cerebrovascular dysfunction in Alzheimerâ€™s disease, with a special emphasis on the blood-brain barrier (BBB). Key accomplishments include:

-   ðŸ“Š Developed a **population pharmacokinetic model** to study AÎ² isoform trafficking and accumulation at the BBB endothelium.\
    *Published in [Molecular Pharmaceutics](https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.1c00549)*
    
![AÎ² PK model](media/Research/abeta_trafficking_model.jpeg)

-   ðŸ”¬ Conducted **flow cytometry, western blot, and confocal imaging** to investigate distinct molecular mechanisms of AÎ² uptake and intracellular trafficking in BBB endothelial cells.\
    *Published in [Molecular Pharmacology](https://molpharm.aspetjournals.org/article/S0026-895X(24)00059-2/abstract)*

-   ðŸ§  Established a **compartmental PK model** to deconvolve plasma kinetics of imaging tracers from dynamic SPECT/CT heart scans.\
    *Published in [Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/article/S0022-3565(24)17050-4/abstract)*
    
![Deconvoltution of plasma PK from heart imaging](media/Research/heart_deconvolution.png)

-   ðŸ§ª Studied the effect of **HDL mimetic peptides and gut microbiome metabolites** on AÎ² accumulation using dynamic imaging and cellular assays.\
    *Published in [Molecular Pharmaceutics](https://pubs.acs.org/doi/full/10.1021/acs.molpharmaceut.4c00633)*

![4F effect on Amyloid beta PK](media/Research/4f_paper.png)

-   ðŸ§¬ Interpreted **time-series transcriptomics** of insulin-exposed BBB endothelial cells and co-authored the manuscript.\
    *Published in [NPJ Systems Biology and Applications](https://www.nature.com/articles/s41540-022-00235-8)*

-   ðŸ” Built a **quantitative systems pharmacology (QSP) model** to simulate insulin signaling and VCAM1 expression in BBB endothelial cells. Integrated proteomics and transcriptomics to study vascular inflammation in Alzheimerâ€™s disease.\
    *Published in [CPT: Pharmacometrics & Systems Pharmacology](https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.13296)*

![QSP model](media/Research/qsp_paper.png)

------------------------------------------------------------------------

## ðŸ§¬ Modeling Neurodegenerative Disease Progression

**Modeling & Simulation Co-op, Biogen Inc. (Jan â€“ Jun 2023)**\
Clinical Pharmacology and Pharmacometrics\
*Supervisor: Dr. Jingxian (JC) Chen*

-   ðŸ“ˆ Conducted **model-based meta-analysis (MBMA)** of MDS-UPDRS data to support early Parkinsonâ€™s disease (PD) trial design.

-   ðŸ§® Built **nonlinear mixed-effect models** (in NONMEM and Monolix) to describe disease progression and time-to-event outcomes.

-   ðŸ“Š Simulated longitudinal endpoint profiles to evaluate study designs and dosing strategies.

-   ðŸ—£ï¸ Presented modeling results and impact to internal project teams and stakeholders.\
    *Presented at ACoP14*

-   ðŸ§ª Developed a **PK/PD model for antisense oligonucleotide (ASO) therapy** in PD and simulated alternate regimens to inform dose optimization.

![PD disease progression model VPC](media/Research/PD_modeling.png)

------------------------------------------------------------------------

## ðŸ§ª Imaging Probe Development for Cancer Detection

**Undergraduate Research Assistant, Shanghai Jiao Tong University (Oct 2016 â€“ Jun 2019)**\
College of Pharmacy\
*Advisor: Dr. Qingqing Meng*

-   ðŸ§« Designed and synthesized **bimodal NIR and PET imaging probes** targeting CYP1B1 for early tumor detection.
-   ðŸ”¬ Evaluated binding affinity and selectivity in CYP1B1-overexpressing cancer cell lines using flow cytometry and confocal imaging.
-   ðŸ§  Performed in vivo/ex vivo biodistribution and tumor visualization imaging.\
    *Published in J. Med. Chem. and ChemBioChem.*

------------------------------------------------------------------------

## ðŸ§ª BBB Drug Delivery for Alzheimerâ€™s Therapy

**Summer Research Intern, University of Tokyo / iCONM (Summer 2018)**\
*Supervisor: Dr. Kazunori Kataoka*

-   ðŸ§ª Prepared **PEGylated anti-AÎ² antibodies** and characterized them with GPC and DLS.
-   ðŸ§  Assessed **brain delivery and pharmacokinetics** of modified antibodies to improve BBB penetration in Alzheimerâ€™s disease.

------------------------------------------------------------------------

## ðŸ”— Related Publications

> ðŸ“‚ See full list on [Google Scholar](https://scholar.google.com/citations?user=4mJXDH4AAAAJ&hl=en)
